Literature DB >> 21684266

Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Maryka Quik1, Xiomara A Perez, Sharon R Grady.   

Abstract

Although a relative newcomer to the nicotinic acetylcholine receptor (nAChR) family, substantial evidence suggests that α6 containing nAChRs play a key role in CNS function. This subtype is unique in its relatively restricted localization to the visual system and catecholaminergic pathways. These latter include the mesolimbic and nigrostriatal dopaminergic systems, which may account for the involvement of α6 containing nAChRs in the rewarding properties of nicotine and in movement. Here, we review the literature on the role of α6 containing nAChRs with a focus on the striatum and nucleus accumbens. This includes molecular, electrophysiological and behavioral studies in control and lesioned animal models, as well as in different genetic models. Converging evidence suggest that the major α6 containing nAChRs subtypes in the nigrostriatal and mesolimbic dopamine system are the α6β2β3 and α6α4β2β3 nAChR populations. They appear to have a dominant role in regulating dopamine release, with consequent effects on nAChR-modulated dopaminergic functions such as reinforcement and motor behavior. Altogether these data suggest that drugs directed to α6 containing nAChRs may be of benefit for the treatment of addiction and for neurological disorders with locomotor deficits such as Parkinson's disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684266      PMCID: PMC3264546          DOI: 10.1016/j.bcp.2011.06.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  136 in total

Review 1.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

Review 2.  ACh/dopamine crosstalk in motor control and reward: a crucial role for alpha 6-containing nicotinic receptors?

Authors:  Paolo Calabresi; Massimiliano Di Filippo
Journal:  Neuron       Date:  2008-10-09       Impact factor: 17.173

3.  Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

Review 4.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

5.  In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors.

Authors:  Ryan M Drenan; Sharon R Grady; Paul Whiteaker; Tristan McClure-Begley; Sheri McKinney; Julie M Miwa; Sujata Bupp; Nathaniel Heintz; J Michael McIntosh; Merouane Bencherif; Michael J Marks; Henry A Lester
Journal:  Neuron       Date:  2008-10-09       Impact factor: 17.173

Review 6.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

7.  Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.

Authors:  Tanuja Bordia; Carla Campos; Luping Huang; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2008-07-23       Impact factor: 4.030

8.  Varenicline reduces alcohol self-administration in heavy-drinking smokers.

Authors:  Sherry A McKee; Emily L R Harrison; Stephanie S O'Malley; Suchitra Krishnan-Sarin; Julia Shi; Jeanette M Tetrault; Marina R Picciotto; Ismene L Petrakis; Naralys Estevez; Erika Balchunas
Journal:  Biol Psychiatry       Date:  2009-02-27       Impact factor: 13.382

Review 9.  Diversity of vertebrate nicotinic acetylcholine receptors.

Authors:  Neil S Millar; Cecilia Gotti
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

10.  Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.

Authors:  S Pons; L Fattore; G Cossu; S Tolu; E Porcu; J M McIntosh; J P Changeux; U Maskos; W Fratta
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

View more
  43 in total

1.  Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2011-12-05       Impact factor: 4.030

2.  Elucidation of molecular impediments in the α6 subunit for in vitro expression of functional α6β4* nicotinic acetylcholine receptors.

Authors:  Anne B Jensen; Kirsten Hoestgaard-Jensen; Anders A Jensen
Journal:  J Biol Chem       Date:  2013-10-01       Impact factor: 5.157

Review 3.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 4.  Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.

Authors:  Sharon R Letchworth; Paul Whiteaker
Journal:  Biochem Pharmacol       Date:  2011-06-28       Impact factor: 5.858

5.  Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Authors:  Paula L Vieira-Brock; Lisa M McFadden; Shannon M Nielsen; Jonathan D Ellis; Elliot T Walters; Kristen A Stout; J Michael McIntosh; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2015-09-21       Impact factor: 4.030

Review 6.  The striatal cholinergic system in L-dopa-induced dyskinesias.

Authors:  X A Perez; T Bordia; M Quik
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

7.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

8.  Diurnal Evening Type is Associated with Current Smoking, Nicotine Dependence and Nicotine Intake in the Population Based National FINRISK 2007 Study.

Authors:  Ulla Broms; Marjaana Pennanen; Kristiina Patja; Hanna Ollila; Tellervo Korhonen; Aino Kankaanpää; Ari Haukkala; Annamari Tuulio-Henriksson; Markku Koskenvuo; Erkki Kronholm; Tiina Laatikainen; Markku Peltonen; Timo Partonen; Jaakko Kaprio
Journal:  J Addict Res Ther       Date:  2012-01-25

9.  Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons.

Authors:  Dustin W DuBois; Joanne C Damborsky; Annette S Fincher; Gerald D Frye; Ursula H Winzer-Serhan
Journal:  Life Sci       Date:  2013-01-24       Impact factor: 5.037

10.  Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.

Authors:  Maryka Quik; Archana Mallela; Matthew Chin; J Michael McIntosh; Xiomara A Perez; Tanuja Bordia
Journal:  Neurobiol Dis       Date:  2012-09-23       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.